Investigational drug · Phase 3
VG081821AC
Also called: VG081821
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson Disease (PD).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VG081821AC"
First trial start
2026
Jul 17, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VG081821AC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease (PD)
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "VG081821AC" as an intervention, largest first.
- VG081821AC Tablets for Early to Mid-stage Parkinson's DiseasePivotal-lookingRecruiting
Zhejiang Vimgreen Pharmaceuticals, Ltd.Industry
NCT07725562 · 152 participants (planned) · Start Jul 17, 2026 · Primary completion Oct 1, 2027
Drug: VG081821AC · For: Parkinson Disease (PD)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- VG081821: A ZM241385-Like A2A Receptor Antagonist With Significant Improvement in Pharmacokinetics.
Sun S, Hu C, Ye J, et al. · Drug Dev Res 2025
Also in development for Parkinson Disease (PD)
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.